Pulmotect Inc.

Developing PUL-042, an inhaled therapeutic designed to prevent and treat respiratory infections

[Pulmotect Inc. @pulmotect]

Get caught up! Check out @abc13houston's recent news report on Pulmotect, Inc. here: https://t.co/QGPKa1Aep7

#MotivationMonday #Health #clinicalresearch #COVID19

[Pulmotect Inc. @pulmotect]

"Scott and his team are hopeful the drug could be used to help frontline workers protect their lungs against the #coronavirus as they treat infected patients. The drug has already passed phase one trials."

#healthcare #COVID19 #HealthcareHeroes #FridayThoughts #Trending

[ABC13 Houston @abc13houston]

Houston company testing drug to protect against COVID-19 https://t.co/G7MUuCRpGi

[Pulmotect Inc. @pulmotect]

#FDA approval in hand, we start two Phase-2 clinical trials against #COVID19 this week.

Details here: https://t.co/0iH2PYwKPC

#covid19 #health #trending #science #coronavirus @US_FDA #TuesdayThoughts #news #healthcare

[Pulmotect Inc. @pulmotect]

@YAYshamsaldeen Thank you - to be clear, it may have potential treatment as well as prophylactic therapeutic effects against Covid-19 in humans. We don't know yet, but we are also hopeful. Stay safe!

[Pulmotect Inc. @pulmotect]

@YAYshamsaldeen @miiiishal1 It may offer clinical benefit in reducing severity post-infection. Antiviral effects after an infection has been established in an animal model are shown here: https://t.co/SAmMQUfqnH

[Pulmotect Inc. @pulmotect]

We would like to express our gratitude to all of our doctors, healthcare workers, scientists, and all other essential workers who are working so hard right now to get us through this #coronavirus pandemic.

#COVID19 #CoronaVirusUpdates #StayHomeSaveLives #NationalDoctorDay

[Pulmotect Inc. @pulmotect]

@pumotect's PUL-042 has successfully prevented & treated a broad range of respiratory infections in animal models, including those of #coronavirus family members #SARS & #MERS. Learn more about PUL-042 below or visit: https://t.co/7cDw6QPYX0

#COVID19 #CoronaUpdate #health #utmb

[Pulmotect Inc. @pulmotect]

@pulmotect is making plans for a phase II clinical trial to test the ability of their immunemodulator PUL-042 in preventing and treating #COVID19. In preclinical studies, PUL-042 has been shown to be effective against other coronaviruses.

#coronavirus #StayHomeSaveLives #houston

[Houston Chronicle @HoustonChron]

Houston researchers test lung inhalant that could protect healthcare workers from COVID-19 https://t.co/HvPRcYb4fQ

[Pulmotect Inc. @pulmotect]

Check out @pulmotect's president, Brenton Scott, as he talks about PUL-042 and the pivot from treating pneumonia in cancer patients to treating pneumonia caused by #COVID19 on @FOX26Houston with @JoseGrinanFOX26

https://t.co/1W4Oon87al

#coronavirus #science #flattenthecurve

[Pulmotect Inc. @pulmotect]

Update March 23 2020 - Pulmotect's Chairman, Leo Linbeck III, provides an update on plans for a Phase II clinical trial to mitigate impact of #COVID19. Stay tune for updates

#coronavirus #research #Houston #WednesdayThoughts #FlattenTheCurve #Science #healthcare #innovation

[Fannin Innovation Studio @FanninStudio]

@pulmotect Chairman & @FanninStudio founder Leo Linbeck III provides an update on Pulmotect’s plans for a Phase II clinical trial to mitigate impact of #COVID19. Learn more: https://t.co/jWVwYKheu8. #coronavirus #FlattenTheCurve #texas

https://t.co/SnokvbNoA1

[Pulmotect Inc. @pulmotect]

Pulmotect, Inc. – Bio-pharmaceutical company developing products for severe respiratory diseases https://t.co/OlVm2ArYcW

[Pulmotect Inc. @pulmotect]

Mimicking the human lung will provide researchers a unique way to investigate new areas of research for #COPD
https://t.co/qit3DioUeR

[Pulmotect Inc. @pulmotect]

A Flu Pandemic Is Coming, But When, and How Bad Will It Be? #flu https://t.co/Iv5L0lj47b

[Pulmotect Inc. @pulmotect]

Check out what we've been up to! https://t.co/7cDw6QPYX0

[Pulmotect Inc. @pulmotect]

9 takeaways on clinical trials from the patient's view | Clinical Innovation + Technology https://t.co/uAdsZzXnYe

[Pulmotect Inc. @pulmotect]

Meet our experienced management team https://t.co/AvQndopdOh

[Pulmotect Inc. @pulmotect]

Our scientific advisory board members include U.S. and european respiratory experts https://t.co/DVcDgdmLf2

[Pulmotect Inc. @pulmotect]

COPD: Changes in the lungs, changes in the microbiome -- ScienceDaily https://t.co/gfUS0Vz4Vy

[Pulmotect Inc. @pulmotect]

How COPD Affects Americans From Coast to Coast #COPD https://t.co/ntbgHYi2dc

[Pulmotect Inc. @pulmotect]

Non-Invasive Ventilation Reduces Death from #COPD Breathing Failure | Medpage Today https://t.co/dPZ05MqieJ